The estimated Net Worth of Vimal Bio Xcel Holdings, In... is at least $4.63 millió dollars as of 4 June 2024. Vimal In owns over 1,427,494 units of BioXcel Therapeutics Inc stock worth over $4,227,026 and over the last few years Vimal sold BTAI stock worth over $399,698.
Sign up
Vimal In BTAI stock SEC Form 4 insiders trading
Vimal has made over 1 trades of the BioXcel Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Vimal sold 1,427,494 units of BTAI stock worth $399,698 on 4 June 2024.
The largest trade Vimal's ever made was selling 1,427,494 units of BioXcel Therapeutics Inc stock on 4 June 2024 worth over $399,698. On average, Vimal trades about 1,427,494 units every 0 days since 2024. As of 4 June 2024 Vimal still owns at least 7,685,501 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Vimal In stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at BioXcel Therapeutics Inc
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta és Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.
What does BioXcel Therapeutics Inc do?
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
What does BioXcel Therapeutics Inc's logo look like?
Complete history of Vimal In stock trades at BioXcel Therapeutics Inc
BioXcel Therapeutics Inc executives and stock owners
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Vimal Mehta,
President, Chief Executive Officer, Co-Founder, Secretary, Director -
Dr. Vimal D. Mehta Ph.D.,
Founder, CEO, Pres, & Director -
Frank Yocca,
Chief Scientific Officer -
Vincent O'Neill,
Chief Medical Officer -
Richard Steinhart,
Chief Financial Officer -
Peter Mueller,
Independent Chairman of the Board -
Sandeep Laumas,
Independent Director -
Dr. Krishnan Nandabalan,
Chief Digital Officer ?& Director -
Michal Votruba,
Independent Director -
John Graziano,
IR Contact Officer -
Reina Benabou,
Senior Vice President, Chief Development Officer -
Will Kane,
Executive Vice President, Chief Commercial Officer -
Krishnan Nandabalan,
Co-Founder, Director, Chief Digital Officer -
Matthew Wiley,
Sr. VP & Chief Commercial Officer -
Dr. Iris Francesconi Ph.D.,
Sr. VP of Marketing, Market Research & Commercial Assessments -
Dr. Frank D. Yocca Ph.D.,
Sr. VP & Chief Scientific Officer -
Richard I. Steinhart MBA,
Sr. VP & CFO -
Dr. Reina Benabou M.D., Ph.D.,
Sr. VP & Chief Devel. Officer -
William P. Kane Jr.,
Exec. VP & Chief Commercial Officer -
Dr. David C. Hanley,
Head of Global Pharmaceutical Devel. and Operations & VP -
Dr. Cedric Burg,
VP and Head of Global Clinical Operations & Project Management -
Javier Rodriguez,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Mary Coleman,
VP of Investment Relations -
Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P.,
Sr. VP & Chief Medical Officer -
Llc Bio Xcel,
10% owner -
Holdings, Inc. Bio Xcel,
10% owner -
Matthew T. Wiley,
Chief Commercial Officer -
Michael Patrick Miller,
Director -
June Bray,
Director -
Vimal Bio Xcel Holdings, In...,
CEO and President